FI971290A - Multippeliskleroosin (MS) ja muiden myeliinikadosta aiheutuvien sairauksien hoito - Google Patents

Multippeliskleroosin (MS) ja muiden myeliinikadosta aiheutuvien sairauksien hoito Download PDF

Info

Publication number
FI971290A
FI971290A FI971290A FI971290A FI971290A FI 971290 A FI971290 A FI 971290A FI 971290 A FI971290 A FI 971290A FI 971290 A FI971290 A FI 971290A FI 971290 A FI971290 A FI 971290A
Authority
FI
Finland
Prior art keywords
multiple sclerosis
treatment
diseases caused
myelin deficiency
myelin
Prior art date
Application number
FI971290A
Other languages
English (en)
Swedish (sv)
Other versions
FI116659B (fi
FI971290A0 (fi
Inventor
Cari Loder
Original Assignee
Cari Loder
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9420116A external-priority patent/GB9420116D0/en
Priority claimed from GBGB9508482.8A external-priority patent/GB9508482D0/en
Application filed by Cari Loder filed Critical Cari Loder
Publication of FI971290A0 publication Critical patent/FI971290A0/fi
Publication of FI971290A publication Critical patent/FI971290A/fi
Application granted granted Critical
Publication of FI116659B publication Critical patent/FI116659B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Fodder In General (AREA)
  • Control Of Indicators Other Than Cathode Ray Tubes (AREA)
  • Control Of El Displays (AREA)
FI971290A 1994-10-05 1997-03-26 Yhdisteiden käyttö valmistettaessa lääkettä multippeliskleroosin (MS) ja muiden myeliinikatotilojen hoitoon FI116659B (fi)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB9420116 1994-10-05
GB9420116A GB9420116D0 (en) 1994-10-05 1994-10-05 A therapeutic drug treatment for compensating for the effects of nerve damage caused by multiple sclerosis and other demyelinating conditions
GBGB9508482.8A GB9508482D0 (en) 1995-04-26 1995-04-26 A therapeutic drug treatment for compensating for the effects of nerve damage caused by multiple sclerosis and other demyelinating conditions, and the product
GB9508482 1995-04-26
PCT/GB1995/002361 WO1996011009A1 (en) 1994-10-05 1995-10-05 Treatment of multiple sclerosis (ms) and other demyelinating conditions using lofepramine in combination with l-phenylalanine, tyrosine or tryptophan and possibly a vitamin b12 compound
GB9502361 1995-10-05

Publications (3)

Publication Number Publication Date
FI971290A0 FI971290A0 (fi) 1997-03-26
FI971290A true FI971290A (fi) 1997-06-02
FI116659B FI116659B (fi) 2006-01-31

Family

ID=26305745

Family Applications (1)

Application Number Title Priority Date Filing Date
FI971290A FI116659B (fi) 1994-10-05 1997-03-26 Yhdisteiden käyttö valmistettaessa lääkettä multippeliskleroosin (MS) ja muiden myeliinikatotilojen hoitoon

Country Status (19)

Country Link
US (2) US6096737A (fi)
EP (1) EP0784476B1 (fi)
JP (1) JPH10508583A (fi)
AT (1) ATE227124T1 (fi)
AU (1) AU710339B2 (fi)
CA (1) CA2200761C (fi)
CZ (1) CZ293873B6 (fi)
DE (1) DE69528773T2 (fi)
DK (1) DK0784476T3 (fi)
ES (1) ES2184808T3 (fi)
FI (1) FI116659B (fi)
HU (1) HU225493B1 (fi)
IS (1) IS1956B (fi)
NO (1) NO314486B1 (fi)
NZ (1) NZ293642A (fi)
PL (1) PL181802B1 (fi)
PT (1) PT784476E (fi)
SK (1) SK281932B6 (fi)
WO (1) WO1996011009A1 (fi)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0942751B1 (en) * 1996-07-05 2002-09-25 The WWK Trust Compositions for the treatment of peripheral neuropathies containing antidepressants and/or monoamine oxidase inhibitors and/or vitamin b12 and/or precursors or inducers of a neurotransmitter
GB9617990D0 (en) * 1996-08-29 1996-10-09 Scotia Holdings Plc Treatment of pain
EP0835660A1 (en) * 1996-10-14 1998-04-15 Gaston Edmond Filomena Merckx Products containing methylcobalamin for the treatment of multiple sclerosis or other demyelinating conditions
US7232830B2 (en) * 1998-06-26 2007-06-19 Elaine A Delack Method for treatment of neurodegenerative diseases and effects of aging
GB9904252D0 (en) * 1999-02-24 1999-04-21 Worsley Andrew P Composition for the treatment of pain
GB9906808D0 (en) * 1999-03-24 1999-05-19 Kilgowan Limited Formulation for treatment of pain
GB2355191A (en) * 1999-10-12 2001-04-18 Laxdale Ltd Combination formulations for fatigue, head injury and strokes
US6555543B2 (en) * 2000-08-04 2003-04-29 Dmi Biosciences, Inc. Method of using diketopiperazines and composition containing them
US8394813B2 (en) 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
US20020147206A1 (en) * 2001-04-05 2002-10-10 Pfizer Inc. Combination treatment of multiple sclerosis (MS), other demyelinating conditions and peripheral neuropathy, especially painful neuropathies and diabetic neuropathy
GB0216027D0 (en) 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
US7169752B2 (en) * 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US6833142B2 (en) * 2002-03-14 2004-12-21 Duane Bennett Formulation for the prevention and treatment of multiple sclerosis and other demyelinating conditions
JP4674317B2 (ja) 2002-10-02 2011-04-20 ディエムアイ アクイジション コーポレイション 疾病の判定および監視
MXPA05008649A (es) * 2003-02-14 2005-11-23 Combinatorx Inc Terapia de combinacion para el tratamiento de desordenes inmunoinflamatorios.
KR20150080004A (ko) 2003-05-15 2015-07-08 앰피오 파마슈티컬스 인코퍼레이티드 Ｔ-세포 매개성 질환의 치료 방법
GB0313630D0 (en) * 2003-06-12 2003-07-16 Wwk Trust The Compositions for the enhanced treatment of depression
TW200522932A (en) * 2003-09-15 2005-07-16 Combinatorx Inc Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
WO2007100668A2 (en) 2006-02-24 2007-09-07 Shire Llc Antidepressant prodrugs
JP5856843B2 (ja) * 2008-05-27 2016-02-10 アンピオ ファーマシューティカルズ，インコーポレイテッド ジケトピペラジンを用いた医薬組成物
WO2011011594A2 (en) * 2009-07-23 2011-01-27 Shriners Hospitals For Children Intracellular toll-like receptors pathways and axonal degeneration
CA2810844C (en) 2010-09-07 2017-03-21 Dmi Acquisition Corp. Diketopiperazine compositions for the treatment of metabolic syndrome and related conditions
WO2013055734A1 (en) 2011-10-10 2013-04-18 Ampio Pharmaceuticals, Inc. Treatment of degenerative joint disease
MY172699A (en) 2011-10-10 2019-12-10 Ampio Pharmaceuticals Inc Implantable medical devices with increased immune tolerance, and methods for making and implanting
MX355446B (es) 2011-10-28 2018-04-18 Ampio Pharmaceuticals Inc Tratamiento de rinitis.
EP2968315B1 (en) 2013-03-15 2020-06-03 Ampio Pharmaceuticals, Inc. Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
WO2016028790A1 (en) 2014-08-18 2016-02-25 Ampio Pharmaceuticals, Inc. Treatment of joint conditions
US11389512B2 (en) 2015-06-22 2022-07-19 Ampio Pharmaceuticals, Inc. Use of low molecular weight fractions of human serum albumin in treating diseases
GB2544630A (en) 2015-11-19 2017-05-24 The Wwk Trust Combinations for the treatment of dementia, and the enhancement of cognitive function
WO2018076108A1 (en) * 2016-10-25 2018-05-03 Uti Limited Partnership Treatment for progressive multiple sclerosis
CA3061340A1 (en) 2017-04-25 2018-11-01 Temple Otorongo Llc Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions
EP3431491A1 (en) * 2017-07-18 2019-01-23 Centre National De La Recherche Scientifique Methods for purifying proteins having a tubulin carboxypeptidase activity and peptidic based inhibitors thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1497306A (en) * 1975-07-03 1978-01-05 Leo Ab Preparation of lofepramine and its hydrochloride
GB2082910A (en) * 1980-08-28 1982-03-17 Berk Pharmaceuticals Ltd Anti-depressant compositions
US4409243A (en) * 1981-11-09 1983-10-11 Julian Lieb Treatment of auto-immune and inflammatory diseases
GB2129299A (en) * 1982-11-09 1984-05-16 Alec James Coppen Pharmaceutical compositions
DE3519687A1 (de) * 1985-06-01 1986-12-04 Veit Arend Aminosaeuren enthaltendes arzneimittel
US4650789A (en) * 1985-10-15 1987-03-17 Commonwealth Medical Corporation Of America Method and composition for increasing production of serotonin
US4843071A (en) * 1986-12-05 1989-06-27 Serotonin Industries Of Charleston Method and composition for treating obesity, drug abuse, and narcolepsy
DE4204102C2 (de) * 1992-02-12 1998-09-24 Kragler Peter Arzneimittel zur Behandlung und/oder Prophylaxe von AIDS und anderen verwandten Erkrankungen

Also Published As

Publication number Publication date
PT784476E (pt) 2003-03-31
PL181802B1 (en) 2001-09-28
DE69528773D1 (de) 2002-12-12
DK0784476T3 (da) 2003-03-17
NO314486B1 (no) 2003-03-31
IS1956B (is) 2004-11-15
HU225493B1 (en) 2007-01-29
HUT77380A (hu) 1998-04-28
SK43897A3 (en) 1998-08-05
WO1996011009A1 (en) 1996-04-18
SK281932B6 (sk) 2001-09-11
NZ293642A (en) 1998-10-28
US6096737A (en) 2000-08-01
IS4454A (is) 1997-03-26
DE69528773T2 (de) 2003-09-04
FI116659B (fi) 2006-01-31
FI971290A0 (fi) 1997-03-26
AU710339B2 (en) 1999-09-16
NO971539L (no) 1997-04-04
CZ99597A3 (en) 1997-11-12
ES2184808T3 (es) 2003-04-16
ATE227124T1 (de) 2002-11-15
EP0784476A1 (en) 1997-07-23
CA2200761C (en) 2008-02-26
US6569850B1 (en) 2003-05-27
CA2200761A1 (en) 1996-04-18
NO971539D0 (no) 1997-04-04
AU3612695A (en) 1996-05-02
CZ293873B6 (cs) 2004-08-18
JPH10508583A (ja) 1998-08-25
PL319830A1 (en) 1997-09-01
EP0784476B1 (en) 2002-11-06

Similar Documents

Publication Publication Date Title
FI971290A (fi) Multippeliskleroosin (MS) ja muiden myeliinikadosta aiheutuvien sairauksien hoito
DE69636343D1 (de) Verwendung von glu-trp dipeptiden zur herstellung eines arzneimittels zur behandlung von verschiedenen gefässneubildung-assozierten erkrankungen
DE69428523D1 (de) Verfahren zur behandlung von gemüts- oder geisteskrankheiten und von gemüts- oder geisteskrankheiten, die von anfällen begleitet sind
DE69434211D1 (de) Phenylacetate und derivate, allein oder in kombination mit anderen verbindungen, zur behandlung von neoplastischen und anderen erkrankungen
PT668763E (pt) Utilizacao de fenserina para a preparacao de medicamentos para tratar doencas do conhecimento
ATE241351T1 (de) Isobutylgaba und dessen derivate zur schmerzbehandlung
EA199800160A1 (ru) Фармацевтическая композиция для лечения сердечно-сосудистых заболеваний, содержащая 3-(2,2,2-триметилгидразиний)пропионат и гамма-бутиробетаин
DE59902666D1 (de) Edelfosin zur behandlung von hirntumoren
WO2003045311A3 (en) Methods for inhibiting or suppressing stenosis of arteriovenous access fistulas and grafts
ATE295731T1 (de) Olanzapine zur behandlung von drogenmissbrauch
HUP0004647A2 (hu) Glükóz-amino-glükánok alkalmazása diabétesszel társult szembetegségek kezelésére szolgáló gyógyszerkészítmények előállítására
ES2183977T3 (es) Combinacion de temozolomida y alfa-interferon para el tratamiento de cancer avanzado.
KR960003741A (ko) 조골세포 증식인자
DE60024408D1 (de) Verwendung von trizyklischen antidepressiva zur behandlung von kopfschmerzen
MX9704887A (es) Composiciones farmaceuticas para el tratamiento de trastornos depresivos.
RU94045317A (ru) Способ лечения вилюйского энцефаломиелита
UA9738A (uk) Спосіб відновлення прохідності стравоходу
UA9737A (uk) Спосіб відновлення прохідності стравоходу
RU94037731A (ru) Способ лечения рассеянного склероза

Legal Events

Date Code Title Description
PC Transfer of assignment of patent

Owner name: AMARIN NEUROSCIENCE LIMITED

Free format text: AMARIN NEUROSCIENCE LIMITED

FG Patent granted

Ref document number: 116659

Country of ref document: FI